Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus PROBAMPACIN.
LAROTID vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic